Patent application number | Description | Published |
20090137782 | SPECIFIC BINDING PROTEINS AND USES THEREOF - The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806. | 05-28-2009 |
20090220510 | Specific binding proteins and uses thereof - The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806. | 09-03-2009 |
20110076232 | SPECIFIC BINDING PROTEINS AND USES THEREOF - The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof. | 03-31-2011 |
20120183471 | SPECIFIC BINDING PROTEINS AND USES THEREOF - The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof. | 07-19-2012 |
20130266573 | Specific binding proteins and uses thereof - The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806. | 10-10-2013 |
20140199361 | INHIBITORY ANTI-FACTOR XII/XIIA MONOCLONAL ANTIBODIES AND THEIR USES - The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use. | 07-17-2014 |
20140255410 | Specific binding proteins and uses thereof - The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806. | 09-11-2014 |
Patent application number | Description | Published |
20130020881 | CIRCUIT ARRANGEMENT AND METHOD FOR INTERRUPTING A CURRENT FLOW IN A DC CURRENT PATH - A DC current path for DC power transmission includes at least a first switching element and a second switching element connected in series. A resonance circuit is configured to be connectable in parallel to the series connection of the at least one first switching element and second switching element by means of a switch. | 01-24-2013 |
20130265693 | CIRCUIT BREAKER - A medium or high-voltage circuit breaker is provided. An arc-extinguishing fluid is stored in a pressure chamber, which is made up by an arcing chamber of the circuit breaker where an electrical arc is extinguished. No tubings or other conduction devices for pressurized fluids are necessary during current interruption. This speeds up contact separation and arc extinguishing. In a first, closed position of the circuit breaker, the pressure chamber is delimited by a sealing wall which is fixed to a movable first arcing contact. The sealing wall acts as a valve and as a piston at the same time, because it opens the outflow of pressurized arc extinguishing fluid and it concurrently actuates arcing contact separation. The arcing chamber enables the stored pressurized arc extinguishing fluid to perform fast contact separation within a few milliseconds and extinguishing a gaseous arc on the same timescale. | 10-10-2013 |
20130278078 | METHOD, CIRCUIT BREAKER AND SWITCHING UNIT FOR SWITCHING OFF HIGH-VOLTAGE DC CURRENTS - A high voltage DC circuit breaker includes a semiconductor switching assembly in series with a mechanical switch. When the semiconductor switching assembly is switched off due to a current fault, a residual current flowing through arresters of the semiconductor switching assembly is switched off by the mechanical switch. A capacitor arranged parallel to the mechanical switch leads to passive resonance effects, which in turn induce current zero crossings in its arc. The current zero crossings allow for reliable extinguishing of the arc. The mechanical switch can be an AC circuit breaker. | 10-24-2013 |
20140005053 | CURRENT-RISE LIMITATION IN HIGH-VOLTAGE DC SYSTEMS | 01-02-2014 |